ADX 104

Drug Profile

ADX 104

Alternative Names: ADX-104

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Aldeyra Therapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Aldehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inborn error metabolic disorders; Sjogren-Larsson syndrome

Most Recent Events

  • 02 Jun 2017 Aldeyra Therapeutics has patent protection and pending patent applications for ADX 104 (Aldeyra Therapeutics Form 10-K, March 2017)
  • 30 Mar 2017 Preclinical trials in Inborn error metabolic disorders in USA (Parenteral)
  • 30 Mar 2017 Preclinical trials in Sjogren-Larrson syndrome in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top